Sarepta buys manufacturing facility

Sarepta Therapeutics (SRPT) acquires a 26-acre multifunctional manufacturing facility in Massachusetts for ~$25M. It will use the site to make investigational exon skipping therapies for Duchenne muscular dystrophy. The transaction is expected to close in July.

The cGMP-qualified facility was built in 1996 and upgraded in 2006. It will support ~40 techs and support staff.

From other sites
Comments (1)
  • tipota
    , contributor
    Comments (5) | Send Message
    It is all over.
    22 May 2014, 11:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs